Lansoprazol Ratiopharm (Lansoprazole)

Lansoprazole is a proton pump inhibitor that reduces gastric acid production, making it effective for several acid‑related gastrointestinal conditions.

• Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining a higher gastric pH.
• Peptic ulcer disease: promotes ulcer healing and prevents recurrence by suppressing acid secretion.
• Erosive esophagitis: facilitates mucosal repair and reduces inflammation in the esophagus.
• Helicobacter pylori eradication regimen: enhances the effectiveness of antibiotic therapy by creating a less acidic gastric environment.

• Lansoprazole irreversibly binds to the H⁺/K⁺‑ATPase enzyme (gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces basal and stimulated gastric acid secretion, leading to an increased gastric pH. The inhibition is sustained for up to 72 hours because new proton pumps must be synthesized for acid secretion to resume, providing prolonged acid control after a single dose.

Lansoprazole may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild pain often resolving without treatment.
• Diarrhea: loose stools that may be transient.
• Nausea: feeling of queasiness, usually mild.
• Abdominal pain: discomfort in the stomach area.
• Flatulence: increased gas production.
• Constipation: difficulty passing stools.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate care.
• Low magnesium levels (hypomagnesemia): muscle cramps, tremors, or cardiac arrhythmias.
• Liver enzyme elevation: signs of hepatic injury, monitored by blood tests.
• Bone fracture risk: especially with long‑term use, due to reduced calcium absorption.
• Interstitial nephritis: kidney inflammation presenting with fever and rash.

Before prescribing Lansoprazole, clinicians should consider several safety measures to minimize risks.

• Assess renal function: dose adjustment may be needed in severe impairment.
• Monitor magnesium levels: prolonged therapy can lead to hypomagnesemia.
• Use caution in hepatic disease: drug metabolism may be altered.
• Avoid long‑term use unless necessary: prolonged suppression increases fracture risk.
• Review concomitant medications: potential interactions may require dose changes.
• Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Lansoprazole can affect the pharmacokinetics of several drugs, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Clopidogrel: reduced activation leading to decreased antiplatelet effect.
• Atazanavir: markedly decreased absorption, compromising antiviral therapy.
• Methotrexate (high dose): increased serum concentrations and toxicity risk.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR, requiring closer monitoring.
• Digoxin: absorption changes may affect serum levels.
• Diazepam: increased plasma concentrations may enhance sedation.